Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $50.00 +0.18%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
OMID, SICP, SCKT, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
OMID, SICP, SCKT, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CTS Corp. (CTS) Tops Q3 EPS by 10c ; Offers Guidance
- PayPal (PYPL) Tops Q3 EPS by 14c; lifts EPS guidance
- Pentair (PNR) Tops Q3 EPS by 10c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
